7 results about "Monobody" patented technology

The present disclosure relates to pharmaceutical and diagnostic compositions comprising macropinocytosis-selective non-binding protein-drug conjugates. These non-binding protein-drug conjugates comprise a non-binding fibronectin type III (FN3) domain linked to a pharmaceutically active or diagnostic moiety. The present disclosure also relates to methods of treatment and diagnosis comprising administering to a subject in need thereof a pharmaceutical composition described herein. TIFF2023551388000007.tif63166

The present application relates to an Intercellular Adhesion Molecule 2 (ICAM-2) binding polypeptide. This ICAM-2 binding polypeptide comprises a fibronectin type III (FN3) domain having at least one modified loop amino acid sequence and, optionally, a modified beta strand. The one or more modified loop sequences, together with the optional beta strand modifications, enable selective binding to ICAM-2. Also disclosed are conjugates that include the ICAM-2 binding polypeptide, polynucleotides encoding the same, and methods of using these materials for inhibiting transplant organ rejection as well as treatment of hypertension and cancer.

The present invention provides a novel substance that stably binds to a surface protein expressed on NK cells. The present invention provides a monobody that binds to a surface protein of an NK cell, wherein the monobody has an amino acid sequence of any one of (1) to (3): (1) an amino acid sequence represented by any one of SEQ ID NOs: A1 to A12; (2) an amino acid sequence given by deletion, substitution, and / or addition of one or more amino acids in an amino acid sequence represented by any one of SEQ ID NOs: A1 to A12 excluding arbitrary amino acids; and (3) an amino acid sequence having an identity of 80% or more with an amino acid sequence represented by any one of SEQ ID NOs: A1 to A12 excluding arbitrary amino acid sequences, wherein X1, X2, X3, X4, X5, and X6 in SEQ ID NOs: A1 to A12 each independently represent an arbitrary amino acid, and n1, n2, n3, n4, n5, and n6 each independently represent an arbitrary natural number.X1n1 X2n2 X3n3 (SEQ ID NO: A1)PIWGRYGTTVRGQTYYWWMLX1n1X2n2 X3n3 (SEQ ID NO: A2)WTWLGYEYYWWDSKPGAIGIX1n1 X2n2 X3n3 (SEQ ID NO: A3)TYWDWGFRWSWARRTHISWFX4n4X5n5 X6n6 (SEQ ID NO: A4)PGYYMWQRGVINGQERAYGHPEHFX4n4X5n5 X6n6 (SEQ ID NO: A5)RYKYHRRINGTQWYVFNEAGDVAGYX1n1X2n2 X3n3 (SEQ ID NO: A6)GPIVSYSWWYHWVGYVNEKYDAWQSYVQX1n1X2n2 X3n3 (SEQ ID NO: A7)QAYWFEYTWWLEVVYDDQWTSGX4n4X5n5 X6n6 (SEQ ID NO: A8)TSPWYNGYDQYKSWNLEEFHX4n4X5n5 X6n6 (SEQ ID NO: A9)TPPWIHKGWVTPYGRKWVGMNGWX1n1X2n2 X3n3 (SEQ ID NO: A10)LWHYYGDQYWWMYVPEYYFNPWX1n1X2n2 X3n3 (SEQ ID NO: A11)TDRNYDITYGMQYWWDGYSYSEEAWYYX4n4X5n5 X6n6 (SEQ ID NO: A12)WSWESYWHGTYTFMKDIPSYY

Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.

The present invention relates to a novel fusion protein in which a monobody specifically bidning to a tumor antigen is linked to L-asparaginase for treating solid cancer more efficiently, and a use thereof, paticularly to a novel fusion protein comprising a recombinant monobody which specifically binds to clareticulin and an L-asparaginase linked to the C-terminus of the recombinant monobody, wherein the recombinant monobody has a peptide that specifically binds to the calreticulin inserted into at least one of the BC loop and the FG loop of human fibronectin domain III (Fn3) as an asparaginase-based novel anticancer agent targeting tumor antigen whose drug delivery efficacy to tumor tissue is enhanced.

The present disclosure is directed to pharmaceutical and diagnostic compositions comprising macropinocytosis selective non-binding protein-drug conjugates. These non-binding protein-drug conjugates comprise a non-binding fibronectin type III (FN3) domain coupled to a pharmaceutically active moiety or a diagnostic moiety. The disclosure is also directed to methods of treatment and diagnosis that involve administering the pharmaceutical compositions described herein to a subject in need.